Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Lanadelumab Improves Quality of Life for Children With HAE and Caregivers

14 November 2026 · By · Wire by Fusion42

Published

14 November 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at hcplive.com →

◆ Verified

Fusion42 · 15 November 2026 · Fusion42 review

Lanadelumab prophylaxis significantly improves quality of life for children aged 2-18 with hereditary angioedema and their caregivers by reducing treatment burden and daily impact, as shown in a retrospective registry analysis.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ ◆ The Wire takeaway

You can now prioritise lanadelumab in paediatric HAE treatment pathways to sharply reduce caregiver workload and patient life disruption. The opportunity is to establish patient access before competitors fully leverage this FDA-approved prophylaxis.

◆ Coverage

1 source · 14 Nov 2026

◆ Related on Wire

◆ Topics

Medtechhaepediatricslanadelumabquality-of-lifecaregiver-burden